Pulmatrix Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Peter Ludlum

Geschäftsführender

US$715.2k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	4.1yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.2yrs

Jüngste Management Updates

Recent updates

Analyseartikel • Aug 02

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Pulmatrix, Inc.'s ( NASDAQ:PULM ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right...

Seeking Alpha • Jul 12

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Pulmatrix (NASDAQ:PULM) on Tuesday said it had dosed the first five subjects in its phase 1 trial evaluating its acute migraine treatment PUR3100. The early-stage trial has been designed to assess the safety, tolerability and pharmacokinetics of inhaled PUR3100. The trial is expected to enroll up to 24 healthy volunteers. PULM expects data from the trial in Q4 2022. PULM stock opened 0.7% lower at $4.57.

Analyseartikel • Feb 22

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analyseartikel • Oct 29

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Aug 16

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Pulmatrix, Inc. ( NASDAQ:PULM ) shareholders will have a reason to smile today, with the covering analyst making...

Analyseartikel • Aug 14

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Pulmatrix, Inc. ( NASDAQ:PULM ) just released its latest second-quarter results and things are looking bullish. Sales...

Analyseartikel • May 27

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyseartikel • Feb 11

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Geschäftsführer

Peter Ludlum (70 yo)

4.1yrs

Amtszeit

US$715,225

Vergütung

Mr. Peter B. Ludlum, CMA, MBA, is Interim Chief Executive Officer of Pulmatrix, Inc. from July 20, 2024. Mr. Ludlum is Interim CFO of Pulmatrix, Inc. from April 18, 2022. Since December 2021, Mr. Ludlum ha...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Higgins	Independent Chairman	11.2yrs	US$85.00k	0% $ 0
David Denning	Member of Pulmazole Clinical Advisory Board	no data	keine Daten	keine Daten
Christopher Cabell	Independent Director	5.9yrs	US$45.00k	0% $ 0
Jonathan Corren	Member of Pulmazole Clinical Advisory Board	no data	keine Daten	keine Daten
Richard Batycky	Independent Director	6.5yrs	US$54.00k	0.00068% $ 31.5
Todd Bazemore	Independent Director	5.6yrs	US$52.50k	0% $ 0
Ritesh Agarwal	Member of Pulmazole Clinical Advisory Board	no data	keine Daten	keine Daten
Cendrine Godet	Member of Pulmazole Clinical Advisory Board	no data	keine Daten	keine Daten
David Stevens	Member of Pulmazole Clinical Advisory Board	no data	keine Daten	keine Daten
Michael Wechsler	Member of Pulmazole Clinical Advisory Board	no data	keine Daten	keine Daten
William Calhoun	Chair of PUR1900 & PUR1800 Clinical Advisory Board	no data	keine Daten	keine Daten
Stephen Silberstein	Chair of PUR3100 (DHE) Clinical Advisory Board	no data	keine Daten	keine Daten

6.2yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrener Vorstand: PULMDie Vorstandsmitglieder gelten als erfahren (6.2 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/14 23:16
Aktienkurs zum Tagesende	2026/05/14 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Pulmatrix, Inc. wird von 1 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Andrew Fein	H.C. Wainwright & Co.

Pulmatrix Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Insufficient new directors

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Recent updates

Pulmatrix, Inc. announced that it has received $1 million in funding

Eos SENOLYTIX, Inc. agreed to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction.

Cullgen Inc. cancelled the acquisition of Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction.

New minor risk - Share price stability

Third quarter 2025 earnings released: US$0.24 loss per share (vs US$0.71 loss in 3Q 2024)

First half 2025 earnings released: US$0.92 loss per share (vs US$1.37 loss in 1H 2024)

First quarter 2025 earnings released: US$0.49 loss per share (vs US$0.23 profit in 1Q 2024)

Full year 2024 earnings released: US$2.62 loss per share (vs US$3.87 loss in FY 2023)

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

New major risk - Share price stability

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Second quarter 2024 earnings released: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine (PUR3100)

First quarter 2024 earnings released: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$10.00

No longer forecast to breakeven

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Geschäftsführer

Vorstandsmitglieder

Unternehmensanalyse und Finanzdaten Status

Datenquellen

Analysemodell und Schneeflocke

Metriken für Industrie und Sektor

Analysten-Quellen